Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15960719 | 0.94 | KCNH2 (0.33) | SMN1; SMN2 | |
| SCHEMBL12654668 | 0.89 | SMN1; SMN2 (0.34) | SMN1; SMN2 | |
| SCHEMBL9963383 | 0.86 | RORC (0.31) | — | |
| SCHEMBL15960708 | 0.86 | RORC (0.33) | — | |
| SCHEMBL25081767 | 0.82 | — | — | |
| SCHEMBL9963298 | 0.81 | CYP2D6 (0.36) | — | |
| SCHEMBL15960715 | 0.80 | KCNH2 (0.36) | — | |
| SCHEMBL9963384 | 0.80 | KCNH2 (0.33) | — | |
| SCHEMBL17014689 | 0.79 | MGLL (0.30) | — | |
| SCHEMBL25081715 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208981-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240208981-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-06-27 | — | — | US | disclosed |
| US-20240025918-A1 | KRAS G12D Inhibitors | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20230381172-A1 | COMBINATIONS OF BCL-2 INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS | ZENO MANAGEMENT, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| WO-2023220046-A1 | TYK2 INHIBITORS | BIOGEN MA INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-11813259-B2 | Benzamide compounds | RECURIUM IP HOLDINGS, LLC (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230210846-A1 | TREATMENT FOR AMYLOIDOSIS | ZENO MANAGEMENT, INC. | 2023-07-06 | — | — | US | disclosed |
| US-9695184-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160235761-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2016-08-18 | — | — | US | disclosed |
| US-20160237093-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2016-08-18 | — | — | US | disclosed |
| US-20160235753-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2016-08-18 | — | — | US | disclosed |
| US-20160237094-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA BIO, Inc. | 2016-08-18 | — | — | US | disclosed |
| US-9353123-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9353122-B2 | Therapeutic compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160002254-A1 | Therapeutic Compounds and Uses Thereof | KALA PHARMACEUTICALS, INC. (US) | 2016-01-07 | — | — | US | disclosed |
| US-20140235657-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235634-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | KALA PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813259-B2 | Benzamide compounds | MKI67, TMBIM6, HDAC1 | SMN1; SMN2 1495/4885 |
| US-11873298-B2 | Compounds and uses thereof | NLN, ACHE, CLN6 | SMN1; SMN2 13/4885 |
| US-20230210846-A1 | TREATMENT FOR AMYLOIDOSIS | TTR, AMY1A, CRYAA | SMN1; SMN2 1027/4885 |
| US-20140235657-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | SMN1; SMN2 2777/4885 |
| US-20160235753-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | SMN1; SMN2 2777/4885 |
| US-20230381172-A1 | COMBINATIONS OF BCL-2 INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS | BCL2, BAD, BAK1 | SMN1; SMN2 1109/4885 |
| US-20160235761-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | SMN1; SMN2 2990/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | SMN1; SMN2 1139/4885 |
| US-20160237094-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | SMN1; SMN2 2777/4885 |
| US-20160237093-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | SMN1; SMN2 2990/4885 |
| US-20230374035-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | SMN1; SMN2 3728/4885 |
| US-20140235634-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | MUC1, CFTR, SLC26A4 | SMN1; SMN2 2990/4885 |
| US-20240208981-A1 | NITROGEN-CONTAINING HETEROCYCLIC POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | HCRTR1, HCRTR2, CCKBR | SMN1; SMN2 2434/4885 |
| US-20160002254-A1 | Therapeutic Compounds and Uses Thereof | PCSK9, CFTR, SLC10A1 | SMN1; SMN2 420/4885 |
| US-20240025918-A1 | KRAS G12D Inhibitors | KRAS, NRAS, HRAS | SMN1; SMN2 3857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.